title: Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
abstract: OBJECTIVE
  Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδ T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for stage IV colorectal cancer (CRC).
  
  
  METHODS
  Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy.
  
  
  RESULTS
  Median age of the 15 patients (4 men, 11 women) was 65 years (range=49-80). Median progression-free survival was 21.3 months. Response rate was 80% (complete response (CR)=26.7%, partial response (PR)=53.3%, stable disease (SD)=20% and progressive disease (PD)=0%). Most adverse events were mild to moderate regarding their intensity and immunotherapy-associated toxicity was minimal.
  
  
  CONCLUSIONS
  Combination of adoptive αβ T cell immunotherapy with chemotherapy for stage IV CRC is feasible and safe.
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan yy4160@yahoo.co.jp.
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Yoshida
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
authors.forename: Masayasu
authors.initials: M
authors.lastname: Naito
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
authors.forename: Teppei
authors.initials: T
authors.lastname: Yamada
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
authors.forename: Naoya
authors.initials: N
authors.lastname: Aisu
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
authors.forename: Kojima
authors.initials: K
authors.lastname: Daibo
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Mera
authors.affiliation: Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Tanaka
authors.affiliation: Seta Clinic Group, Tokyo, Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Naito
authors.affiliation: Seta Clinic Group, Tokyo, Japan.
authors.forename: Kosei
authors.initials: K
authors.lastname: Yasumoto
authors.affiliation: Seta Clinic Group, Tokyo, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kamigaki
authors.affiliation: Seta Clinic Group, Tokyo, Japan.
authors.forename: Shigenori
authors.initials: S
authors.lastname: Goto
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yamashita
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
authors.forename: Suguru
authors.initials: S
authors.lastname: Hasegawa
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010071:Oxaloacetates; D012189:Retrospective Studies; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000637:transplantation; D016896:Treatment Outcome
chemical_list: D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil
keywords: Colorectal cancer; XELOX; chemotherapy; immunotherapy; αβT